<DOC>
	<DOCNO>NCT01885676</DOCNO>
	<brief_summary>- Androgenetic alopecia ( AGA ) common baldness common cause hair loss men woman cause action androgen genetically predispose individual . - This clinical trial design evaluate efficacy safety use preparation autologous plasma rich growth factor ( PRGF-Endoret ) treatment androgenetic alopecia .</brief_summary>
	<brief_title>Plasma Rich Growth Factors ( PRGF-Endoret ) Treatment Androgenetic Alopecia</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Androgenetic alopecia accord follow scale : Men : Hamilton/Norwood Scale : grade IIVI Women : Ludwig Scale grade III . Possibility followup study No androgenetic alopecia Telogen anagen effluvium Active inflammation infection intervention area Presence active systemic infection . Background cancerous precancerous lesion . Background connective rheumatic disease . Suffering serious blood disorder . To undergone treatment alopecia previous 6 month . Previous hair implant Intake drug affect hair loss . Be undergoing immunosuppressive therapy and/or anticoagulant . Known intolerance mesotherapy . Taking contraceptive contain cyproterone acetate . Pregnancy In general , limitation would prevent proper application treatment right monitor efficacy variable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>